LindsayBKilburnMD

Pediatric Hematology & Oncology • Washington, DC

Pediatric Neuro-Oncology

Attending physician in Neuro-Oncology and Director of Experimental Therapeutics for the Brain Tumor Institute at Children's National Hospital and Associate Professor of Pediatrics at the George Washington School of Medicine and Health Sciences

Join to view full profile

Dr. Kilburn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kilburn's full profile

Already have an account?

Office
111 Michigan Ave NW
Center for Cancer and Blood disorders
Washington, DC 20010
Phone+1 202-476-2800

Summary

I am board certified in pediatric hematology and oncology as well as clinical pharmacology. I care for children with newly diagnosed and recurrent brain and spinal cord tumors. My research focuses on the development and translation of new therapies for children with brain tumors with a particular focus on novel therapies for glioma and medulloblastoma and combination therapies with focused ultrasound.

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2004 - 2007
Eastern Virginia Medical SchoolResidency, Pediatrics, 2001 - 2004
Eastern Virginia Medical SchoolClass of 2001

Certifications & Licensure

DC State Medical License 2010 - 2024
TX State Medical License 2007 - 2011
VA State Medical License 2001 - 2004
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Start of enrollment: 2009 Feb 25
Completed
Phase 1
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
Active, not recruiting
Phase 2
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2015 Jul 14
Completed
Phase 1
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Start of enrollment: 2016 Jan 07
Completed
Phase 1
Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma Start of enrollment: 2016 Apr 01
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas Start of enrollment: 2016 Nov 18
Completed
Phase 1, Phase 2
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery Start of enrollment: 2018 Nov 26
Completed
Phase 2, Phase 3
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24
Terminated
Phase 1, Phase 2
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Start of enrollment: 2019 Jul 25
Suspended
Phase 1, Phase 2
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Start of enrollment: 2020 Dec 09
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

60 citations
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma
Nadia Barahmani, Sarah C. Carpentieri, Xio Nan Li, Tao Wang, Yumei Cao
Neuro-Oncology. 2009-06-01
52 citations
Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002).
Theodore Nicolaides, Kellie J. Nazemi, John Robertson Crawford, Lindsay Kilburn, Jane E. Minturn
Oncotarget. 2020-05-26
28 citations
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, Daniel Landi, Jasper van der Lugt
Nature Medicine. 2024-01-01

Journal Articles

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Eugene I Hwang, Cassie Kline, Soonmee Cha, Michael Prados, Lindsay B Kilburn, Nalin Gupta, Roger J Packer, Suresh N Magge, Clinical Cancer Research

Press Mentions

SonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain CancerSeptember 13th, 2022
“Liquid Biopsies” Could Track Diffuse Midline GliomasAugust 21st, 2019
Tovorafenib Approved for Some Children with Low-Grade GliomaAugust 8th, 2024